| 1/15 | US=34 / Câncer Alves VAF, Ribeiro Júnior U. Marcadores preditivos de resposta terapêutica. In: Guimarães JRQ. Manual de oncologia. 3ª ed. São Paulo: BBS Editora, 2008. p. 205-16. MARCADORES MOLECULARES; MOLECULAS RELACIONADAS AO CICLO CELULAR; APOPTOSE; FATORES DE CRESCIMENTO EPIDERMICO; VALOR PROGNOSTICO DO ESTUDO DE HER-2; PROPOSTA DE CONDUTA; EGFR/HER-1; CD-117/C-KIT; MARCADORES DE ANGIOGENESE E DA DENSIDADE DE MICROVASOS; TIMIDILATO-SINTASE (TS); COX-2 |
| 2/15 | US=89 / Enfermagem Fink RM, Ruxicka DL, Gates RA. Manejo da dor. In: Gates RA, Fink RM. Segredos em enfermagem oncológica: respostas necessárias ao dia-a-dia. 3ªed. São Paulo: Artmed, 2009. p. 454-76. CLASSIFICACAO DAS DORES; DISFUNCAO COGNITIVA; PLACEBO; ADICTO; AINES; COX-2; ANTIDEPRESSIVOS TRICICLICOS; DOR NEUROPATICA; CORTICOSTEROIDES; ESPASMOS MUSCULARES; CAPSAICINA; DOR OSSEA METASTATICA; ROTACAO DE OPIOIDES; DEPRESSAO RESPIRATORIA; MORFINA; SONDA DE GASTROSTOMIA; METADONA; FENTANIL; TRAMADOL; ACP; INTRATECAL; EPIDURAL; MEDULA ESPINHAL |
| 3/15 | US=16 / Estatística Xu XC. Risk factors and gene expression in esophageal cancer. In: Verma M. Cancer epidemiology. New York: Humana Press, 2009. p. 335-60. (Methods in Molecular Biology, 471) ISBN 978-1-58829-987-1. CANCER DE ESOFAGO; FATORES DE RISCO; EXPRESSAO GENICA; TABAGISMO; ALCOOLISMO; REFLUXO GASTROESOFAGICO; ALTERACOES GENETICAS; CANCER. PREVENCAO; ESOFAGO DE BARRET; ADENOCARCINOMA ESOFAGICO; MUTACAO DO GENE P53; ALTERACAO DO GENE P16; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMAL (EGFR); CADERINA-E; COX-2; QUIMIOPREVENCAO; ACIDOS RETINOICOS; ANTI-INFLAMATORIOS NAO ESTEROIDES; EGCG; CURCUMINA |
| 4/15 | US=9 / Quimioterapia Ohshima H, Tomono S, Lai YL, Miyoshi N. Inflammation-induced carcinogenesis and chemoprevention. In: Knasmüller S, DeMarini DM, Johnson I, Gerhäuser C. Chemoprevention of cancer and DNA damage by dietary factors. Weinheim: Wiley-VCH, 2009. p. 145-52. ISBN 978-3-527-32058-5. CARCINOGENESE INDUZIDA POR INFLAMACAO; QUIMIOPREVENCAO; FATOR NUCLEAR-KB; INOS; COX-2; ROS |
| 5/15 | US=35 / Gastro Kiguchi K, DiGiovanni J. Role of growth factor-signaling pathways. In: Thomas CR Junior, Fuller CD. Biliary tract and gallbladder cancer: diagnosis and therapy. New Jersey: DemosMedical, 2009. p. 19-34. ISBN 978-1-933864-42-6. NEOPLASIAS DO TRATO BILIAR; CANCER DE VESICULA BILIAR; FATOR DE CRESCIMENTO; FAMILIA ERBB; RECEPTOR DO FATOR DE CRESCIMENTO INSULIN-LIKE 1; C-MET; MTOR; COX-2 |
| 6/15 | US=60 / Biol/Mol Leung KC, Chen GG. Cyclooxygenase 2 and its metabolites: implications for lung cancer therapy. In: Chen GG, Lai PBS. Apoptosis in carcinogenesis and chemotherapy: apoptosis in cancer. New York: Springer, 2009. p. 251-72. ISBN 978-1-4020-9596-2. APOPTOSE; MORTE CELULAR PROGRAMADA; CANCER DE PULMAO; CICLOOXIGENASE 2; PROSTAGLANDINA; COX-2; QUIMIOTERAPIA |
| 7/15 | US=85 / Biol/Mol Hwang JT, Lee YK, Shin JI, Park OJ. Anti-inflammatory and anticarcinogenic effect of genistein alone or in combination with caspsaicin in TPA-treated rat mammary glans or mammary cancer cell line. In: Diederich M. Natural compounds and their role in apoptotic cell signaling pathways. Boston: Blackwell, 2009. p. 415-20. (Annals of the New York Academy of Sciences Vol 1171) ISBN 978-1-57331-737-5. TRATAMENTO DE COMBINACAO DE GENISTEINA E DE CAPSAICINA; APOPTOSE; COX-2; AMPK; EFEITOS ANTI-INFLAMATORIOS E ANTICARCINOGENICA |
| 8/15 | US=85 / Biol/Mol Kim SY, Jun TW, Lee YS, Na HK, Surh YJ, Song W. Effects of exercise on cyclooxygenase-2 expression and nuclear factor-&*1179;B DNA binding in human peripheral blood mononuclear cells. In: Diederich M. Natural compounds and their role in apoptotic cell signaling pathways. Boston: Blackwell, 2009. p. 464-71. (Annals of the New York Academy of Sciences Vol 1171) ISBN 978-1-57331-737-5. |
| 9/15 | US=85 / Biol/Mol Lee YK, Park SI, KimYM, Park OJ. Regulatory effect of the AMPK-COX-2 signaling pathway in curcumin-induced apoptosis in HT-29 colon cancer cells. In: Diederich M. Natural compounds and their role in apoptotic cell signaling pathways. Boston: Blackwell, 2009. p. 489-94. (Annals of the New York Academy of Sciences Vol 1171) ISBN 978-1-57331-737-5. APOPTOSE; CURCUMINA; AKT; AMPK; COX-2; PARADA DO CICLO CELULAR; HT-29COLON CELULAS CANCEROSAS; P53 TIPO SELVAGEM |
| 10/15 | US=85 / Biol/Mol Park IJ, Lee YK, Hwang JT, Kwon DY, Ha J, Park OJ. Green tea catechin controls apoptosis in colon cancer cells by attenuation of H2O2-stimulated COX-2 expression via the AMPK signaling pathway at low-dose H2O2. In: Diederich M. Natural compounds and their role in apoptotic cell signaling pathways. Boston: Blackwell, 2009. p. 538-44. (Annals of the New York Academy of Sciences Vol 1171) ISBN 978-1-57331-737-5. EGCG; COX-2; AMPK; HT-29 CANCER DE CELULAS DO COLON; BAIXAS DOSES DE H2O2; APOPTOSE; P53 TIPO SELVAGEM |
| 11/15 | US=96 / Biol/Mol Cusimano A, Foderà D, Lampiasi N, Azzolina A, Notarbartolo M, Giannitrapani L, D'Alessandro N, Montalto G, Cervello M. Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. In: Bradlow KL, Carruba G. Steroid enzymes and cancer. Boston: Blackwell, 2009. p. 300-8. (Annals of the New York Academy of Science,v.155) ISBN 9978-1-57331-745-0. HCC; EP RECEPTORES; COX-1; COX-2; NSAIDS; HEPATOCELLULAR CARCINOMA |
| 12/15 | US=101 / Câncer Wu KK, Liou JY. Cyclooxygenase inhibitors induce induce colon cancer cell apoptosis Via PPAR&*948;&*8594;14-3-3&*949; pathway. In: Kozlov SV, editor. Inflammation and cancer: methods and protocols. volume 2, molecular analysis and pathways. New York: Humana Press, 2009. p. 295-307. (Methods in Molecular Biology, 512) ISBN 978-1-60327-529-3. COX-2; NSAIDS; COX-2 INIBIDORES; PPAR&*948;; 14-3-3 PROTEINAS; APOPTOSE; CANCER DE COLON |
| 13/15 | US=1 / Dor/Paliativo Sakata RK, Issy AM. Antiinflamatórios. In: ___. Guia de dor. 2ª ed. Barueri: Manole, 2008. p. 151-62. (Série Guias de medicina ambulatorial e hospitalar da UNIFESP-EPM) ISBN 85-2042633-3. ANTIINFLAMATORIOS NAO-ESTEROIDES; CLASSIFICACAO; INDICACOES; MECANISMOS DE ACAO; COX-1; COX-2; VIAS DE ADMINISTRACAO; INTERACOES MEDICAMENTOSAS; EFEITOS COLATERAIS |
| 14/15 | US=67 / Biol/Mol Bertagnolli M, Viner JL, Hawk ET. Cyclooxygenase-2 as a target for cancer prevention and treatment. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 509-41. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CICLOOXIGENASE-2; COX-2; CANCER. PREVENCAO; CANCER. TRATAMENTO; INFLAMACAO; PROSTAGLANDINA; TUMORIGENESE |
| 15/15 | US=90 / Biol/Mol Buck E, Eyzaguirre A, Iwata KK. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: utilizing combination of molecular targeted agents to sensitize tumor cells to EGFR inhibitors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 369-82. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1. EMT; TRANSICAO EPITELIAL MESENQUIMAL; ERLOTINIB; EGFR; IGF-1R; ER; HER3; MTOR; HDAC; SRC; COX-2 |